HCV Treatment
Allergy Drug Inhibits Hepatitis C Virus Replication in Mouse Study
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 17 April 2015 00:00
- Written by NIH
The over-the-counter allergy medication chlorcyclizine HCl, or CCZ, was found to be a potent inhibitor of hepatitis C virus (HCV) genotype 1b and 2a replication, according to a laboratory study described in the April 8 edition of Science Translational Medicine. The study authors suggest that this older drug could potentially be an affordable component of combination treatment. A Phase 1 clinical trial is now underway.
Janssen Interferon-Free Regimen with Simeprevir Cures Most Patients with Genotype 1 HCV
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 10 April 2015 00:00
- Written by Medivir
A 12-week all-oral regimen containing the FDA-approved HCV protease inhibitor simeprevir (Olysio) plus 2 investigational direct-acting antivirals drugs being developed by Janssen cured up to 95% of people with genotype 1 hepatitis C, according to study findings presented at the Asian Pacific Association for the Study of the Liver (APASL) conference last month in Istanbul.
FDA Warns of Heart Risk When Combining Amiodarone with Sovaldi or Harvoni
- Details
- Category: Drug Advisories & Warnings
- Published on Wednesday, 25 March 2015 00:00
- Written by FDA
The new oral hepatitis C drug sofosbuvir, either in the sofosbuvir/ ledipasvir coformulation (Harvoni) or with other direct-acting antivirals, should not be taken with the anti-arrhythmic medication amiodarone, the U.S. Food and Drug Association (FDA) and Gilead Sciences warned after several patients developed decreased heart rate (bradycardia) and 1 had a fatal heart attack when they combined these drugs.
CROI 2015: Good Sofosbuvir/Ledipasvir Adherence in SYNERGY and ERADICATE Trials
- Details
- Category: Approved HCV Drugs
- Published on Friday, 10 April 2015 00:00
- Written by Liz Highleyman
Overall adherence rates ranged from 96% to nearly 100% in 2 clinical trials of sofosbuvir/ledipasvir (Harvoni) treatment in an urban population of hepatitis C and HIV/HCV coinfected patients traditionally considered difficult to treat, researchers reported at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle. Adherence dropped off over time, however, underlining the importance of short-duration therapy.
FDA Will Consider Approval of Daclatasvir for Genotype 3 Hepatitis C Treatment
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 17 March 2015 00:00
- Written by Bristol-Myers Squibb
The U.S. Food and Drug Administration (FDA) has accepted Bristol-Myers Squibb's application for approval of stand-alone daclatasvir (Daklinza) for the treatment of genotype 3 hepatitis C virus (HCV), to be used in combination with sofosbuvir (Sovaldi), the company announced last week.
More Articles...
- CROI 2015: Re-infection Due to Ongoing Risk Is Probably the Cause of HCV Recurrence After SVR
- CROI 2015: Sustained Virological Response Represents a Long-term Cure for Hepatitis C
- CROI 2015: Hepatitis C -- Mission Accomplished? [VIDEO]
- Coverage of the 2015 Conference on Retroviruses and Opportunistic Infections
Web Design and Development by